UCB-35440

UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation[1][2].

Product Specifications

CAS Number

[299460-62-1]

UNSPSC

12352005

Target

Histamine Receptor; Lipoxygenase

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ucb-35440.html

Purity

99.38

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

O=C(N)C1=CC(C#CCCN(C(N)=O)O)=CC=C1OCCN2CCN([C@@H](C3=CC=C(Cl)C=C3)C4=CC=CC=C4)CC2

Molecular Formula

C31H34ClN5O4

Molecular Weight

576.09

References & Citations

[1]Giannaras A, et al. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol. 2005 Jan 4;506 (3) :265-71. |[2]Oliver Werz, et al. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds. Expert Opin Ther Patents. 2005 May 10; 15 (5) :505-519.